Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 June 2024

View source ↗

Summary

PRAC started a safety review of metamizole and an investigation into potential links between CAR T-cell therapies and secondary cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Kymriah (tisagenlecleucel)
• Metamizole (metamizole)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)

Snippet

Start of review of painkiller metamizole and risk of secondary cancers with CAR T-cell medicines.